Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Capital Expenditures (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Capital Expenditures for 14 consecutive years, with $143000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 98.36% year-over-year to $143000.0, compared with a TTM value of $4.3 million through Dec 2025, down 83.42%, and an annual FY2025 reading of $12.9 million, down 28.15% over the prior year.
  • Capital Expenditures was $143000.0 for Q4 2025 at Enanta Pharmaceuticals, down from $1.5 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $11.5 million in Q3 2024 and bottomed at -$536000.0 in Q2 2023.
  • Average Capital Expenditures over 5 years is $2.1 million, with a median of $760500.0 recorded in 2021.
  • Peak annual rise in Capital Expenditures hit 51500.0% in 2022, while the deepest fall reached 320.0% in 2022.
  • Year by year, Capital Expenditures stood at $363000.0 in 2021, then soared by 197.25% to $1.1 million in 2022, then dropped by 27.06% to $787000.0 in 2023, then soared by 1011.18% to $8.7 million in 2024, then plummeted by 98.36% to $143000.0 in 2025.
  • Business Quant data shows Capital Expenditures for ENTA at $143000.0 in Q4 2025, $1.5 million in Q3 2025, and $155000.0 in Q2 2025.